MORRISVILLE, N.C., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, beginning at approximately 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California.
Access to a live, audio-only webcast will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A replay and transcript of the webcast will be archived on the company's website for at least 30 days.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4400
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Patrick Wallace
919.328.4383
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$14.09 |
| Daily Change: | -0.06 -0.42 |
| Daily Volume: | 1,416,581 |
| Market Cap: | US$1.200B |
June 23, 2025 June 02, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
